Jefferies assumed coverage of Privia Health with a Buy rating with a price target of $25, down from $33. The firm’s long-term conviction in the value-based care opportunity remains intact due to low penetration, payor and government focus on transitioning to value-based frameworks, and an unchanged underlying need for better and lower cost healthcare. However, the analyst is “realistic on near-term headwinds” facing the Medicare Advantage space and says challenges in the public value-based care world “warrant a more selective stance.” Jefferies names Privia Health (PRVA) and Apollo Medical (AMEH) its top picks saying they are stable, high growth compounders with best-in-class free cash flow profiles.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRVA:
- Privia Health Group, Inc. (PRVA) Q4 Earnings Cheat Sheet
- Privia Health downgraded to Neutral at BofA on slow ramp of VBC
- Privia Health downgraded to Neutral from Buy at BofA
- Evercore says Apollo deal ‘doesn’t sound like a big risk’ to Privia
- Privia Health Appoints Edward C. Fargis as General Counsel
Questions or Comments about the article? Write to editor@tipranks.com